Paul Vigneron, Maria Stella Franzè, Julia Chalaye, Vania Tacher, Anna Sessa, Alain Luciani, Hicham Kobeiter, Hélène Regnault, Ancuta Bejan, Julien Calderaro, Rami Rhaiem, Daniele Sommacale, Giovanni Raimondo, Vincent Leroy, Raffaele Brustia, Giuliana Amaddeo
{"title":"巴塞罗那肝癌诊所（BCLC）肝细胞癌分期的选择性内放射治疗：文献综述。","authors":"Paul Vigneron, Maria Stella Franzè, Julia Chalaye, Vania Tacher, Anna Sessa, Alain Luciani, Hicham Kobeiter, Hélène Regnault, Ancuta Bejan, Julien Calderaro, Rami Rhaiem, Daniele Sommacale, Giovanni Raimondo, Vincent Leroy, Raffaele Brustia, Giuliana Amaddeo","doi":"10.21037/hbsn-23-504","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and objective: </strong>Selective internal radiation therapy (SIRT) represents an endovascular treatment option for patients with hepatocellular carcinoma (HCC). Its use is widely recognized in the intermediate and advanced HCC, but it has become more prevalent in recent years in different Barcelona Clinic Liver Cancer (BCLC) stages. The aim of this review is to summarize the role of SIRT and its clinical implications through different stages of HCC.</p><p><strong>Methods: </strong>A literature review of papers on this topic was performed using PubMed MEDLINE, focusing exclusively on the role of yttrium-90 SIRT across all BCLC stages and comparing it with other treatments. Only English-language papers currently available until September 2023 were considered.</p><p><strong>Key content and findings: </strong>Many studies have shown that SIRT is a promising tool with multiple uses, such as tumour control in the context of bridge-to-liver transplantation or resection, tumour downstaging, and curative therapy in selected patients. Therefore, according to the recent update of BCLC staging system criteria, SIRT now emerges as a potential curative treatment for early-stage HCC patients, serving as an alternative when ablation or resection is not feasible. It is also a promising treatment compared to transarterial chemoembolization (TACE) as well as in combination with immunotherapies.</p><p><strong>Conclusions: </strong>SIRT is a safe and effective treatment for selected patients at all BCLC stages of HCC. Therefore, due to its numerous advantages, SIRT may prove useful in many complex HCC treatment situations in the near future.</p><p><strong>Keywords: </strong>Hepatocellular carcinoma (HCC); radioembolization; yttrium-90 (<sup>90</sup>Y); selective internal radiation therapy (SIRT); transarterial radioembolization (TARE).</p>","PeriodicalId":12878,"journal":{"name":"Hepatobiliary surgery and nutrition","volume":"13 6","pages":"974-990"},"PeriodicalIF":6.1000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11634413/pdf/","citationCount":"0","resultStr":"{\"title\":\"Selective internal radiation therapy across Barcelona Clinic Liver Cancer (BCLC) stages of hepatocellular carcinoma: literature review.\",\"authors\":\"Paul Vigneron, Maria Stella Franzè, Julia Chalaye, Vania Tacher, Anna Sessa, Alain Luciani, Hicham Kobeiter, Hélène Regnault, Ancuta Bejan, Julien Calderaro, Rami Rhaiem, Daniele Sommacale, Giovanni Raimondo, Vincent Leroy, Raffaele Brustia, Giuliana Amaddeo\",\"doi\":\"10.21037/hbsn-23-504\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background and objective: </strong>Selective internal radiation therapy (SIRT) represents an endovascular treatment option for patients with hepatocellular carcinoma (HCC). Its use is widely recognized in the intermediate and advanced HCC, but it has become more prevalent in recent years in different Barcelona Clinic Liver Cancer (BCLC) stages. The aim of this review is to summarize the role of SIRT and its clinical implications through different stages of HCC.</p><p><strong>Methods: </strong>A literature review of papers on this topic was performed using PubMed MEDLINE, focusing exclusively on the role of yttrium-90 SIRT across all BCLC stages and comparing it with other treatments. Only English-language papers currently available until September 2023 were considered.</p><p><strong>Key content and findings: </strong>Many studies have shown that SIRT is a promising tool with multiple uses, such as tumour control in the context of bridge-to-liver transplantation or resection, tumour downstaging, and curative therapy in selected patients. Therefore, according to the recent update of BCLC staging system criteria, SIRT now emerges as a potential curative treatment for early-stage HCC patients, serving as an alternative when ablation or resection is not feasible. It is also a promising treatment compared to transarterial chemoembolization (TACE) as well as in combination with immunotherapies.</p><p><strong>Conclusions: </strong>SIRT is a safe and effective treatment for selected patients at all BCLC stages of HCC. Therefore, due to its numerous advantages, SIRT may prove useful in many complex HCC treatment situations in the near future.</p><p><strong>Keywords: </strong>Hepatocellular carcinoma (HCC); radioembolization; yttrium-90 (<sup>90</sup>Y); selective internal radiation therapy (SIRT); transarterial radioembolization (TARE).</p>\",\"PeriodicalId\":12878,\"journal\":{\"name\":\"Hepatobiliary surgery and nutrition\",\"volume\":\"13 6\",\"pages\":\"974-990\"},\"PeriodicalIF\":6.1000,\"publicationDate\":\"2024-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11634413/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Hepatobiliary surgery and nutrition\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.21037/hbsn-23-504\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/6/6 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hepatobiliary surgery and nutrition","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21037/hbsn-23-504","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/6 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景和目的：选择性内放射治疗（SIRT）是肝细胞癌（HCC）患者血管内治疗的一种选择。它在中晚期HCC中的应用得到广泛认可，但近年来在巴塞罗那临床肝癌（BCLC）的不同阶段中越来越普遍。这篇综述的目的是总结SIRT在HCC不同阶段的作用及其临床意义。方法：使用PubMed MEDLINE对该主题的论文进行文献回顾，专注于钇-90 SIRT在所有BCLC阶段的作用，并将其与其他治疗方法进行比较。仅考虑2023年9月前可用的英语论文。关键内容和发现：许多研究表明，SIRT是一种有前景的工具，具有多种用途，如在桥肝移植或切除背景下的肿瘤控制，肿瘤分期降低，以及在选定的患者中进行根治性治疗。因此，根据最近更新的BCLC分期系统标准，SIRT现在成为早期HCC患者的潜在治愈治疗方法，可作为不可行的消融或切除术的替代方法。与经动脉化疗栓塞（TACE）以及与免疫疗法联合相比，它也是一种有希望的治疗方法。结论：SIRT是一种安全有效的治疗方法，适用于所有BCLC期HCC患者。因此，由于其众多优势，在不久的将来，SIRT可能在许多复杂的HCC治疗情况中被证明是有用的。关键词：肝细胞癌；radioembolization;钇- 90 y (90);选择性内放射治疗（SIRT）；经动脉放射栓塞（TARE）。
Selective internal radiation therapy across Barcelona Clinic Liver Cancer (BCLC) stages of hepatocellular carcinoma: literature review.
Background and objective: Selective internal radiation therapy (SIRT) represents an endovascular treatment option for patients with hepatocellular carcinoma (HCC). Its use is widely recognized in the intermediate and advanced HCC, but it has become more prevalent in recent years in different Barcelona Clinic Liver Cancer (BCLC) stages. The aim of this review is to summarize the role of SIRT and its clinical implications through different stages of HCC.
Methods: A literature review of papers on this topic was performed using PubMed MEDLINE, focusing exclusively on the role of yttrium-90 SIRT across all BCLC stages and comparing it with other treatments. Only English-language papers currently available until September 2023 were considered.
Key content and findings: Many studies have shown that SIRT is a promising tool with multiple uses, such as tumour control in the context of bridge-to-liver transplantation or resection, tumour downstaging, and curative therapy in selected patients. Therefore, according to the recent update of BCLC staging system criteria, SIRT now emerges as a potential curative treatment for early-stage HCC patients, serving as an alternative when ablation or resection is not feasible. It is also a promising treatment compared to transarterial chemoembolization (TACE) as well as in combination with immunotherapies.
Conclusions: SIRT is a safe and effective treatment for selected patients at all BCLC stages of HCC. Therefore, due to its numerous advantages, SIRT may prove useful in many complex HCC treatment situations in the near future.
期刊介绍：
Hepatobiliary Surgery and Nutrition (HBSN) is a bi-monthly, open-access, peer-reviewed journal (Print ISSN: 2304-3881; Online ISSN: 2304-389X) since December 2012. The journal focuses on hepatopancreatobiliary disease and nutrition, aiming to present new findings and deliver up-to-date, practical information on diagnosis, prevention, and clinical investigations. Areas of interest cover surgical techniques, clinical and basic research, transplantation, therapies, NASH, NAFLD, targeted drugs, gut microbiota, metabolism, cancer immunity, genomics, and nutrition and dietetics. HBSN serves as a valuable resource for professionals seeking insights into diverse aspects of hepatobiliary surgery and nutrition.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
